Cerebral Palsy: Types, Causes, and Lifetime Management

1 in 345 Children: The Most Common Physical Disability of Childhood

Cerebral palsy (CP) affects approximately 1 in 345 children in the United States, according to 2023 CDC surveillance data — making it the most common physical disability of childhood. An estimated 764,000 children and adults in the US have CP, with approximately 10,000 new cases diagnosed each year. Despite its prevalence and decades of research, cerebral palsy is not a single disease but a heterogeneous group of permanent disorders of movement and posture, caused by non-progressive damage to the developing brain during fetal development, birth, or early childhood. The brain lesion itself is static — it does not worsen over time — but its functional consequences evolve as the child grows, sometimes improving with intervention and development, sometimes presenting new challenges with aging.

CP is diagnosed based on clinical presentation — delayed motor milestones, abnormal tone and reflexes, and characteristic movement patterns — typically before age 2–3, though complex cases may be identified later. The diagnosis requires neuroimaging to characterize the underlying brain lesion and to exclude progressive conditions that might mimic CP.

Causes and Timing of Brain Injury

The majority of CP cases — approximately 80% — result from injury occurring during the prenatal period, not during delivery. Common prenatal causes include:

• Periventricular leukomalacia (PVL): ischemic white matter injury near the ventricles, most common in premature infants born before 32 weeks gestation. White matter injury disrupts the corticospinal tracts running through the periventricular region, producing the characteristic leg-dominant spastic diplegia pattern of prematurity-related CP.
• Cortical and subcortical malformations: polymicrogyria, lissencephaly, schizencephaly, and heterotopia — brain developmental anomalies that can cause CP with or without intellectual disability and epilepsy.
• Intraventricular hemorrhage (IVH): bleeding into and around the ventricles in premature infants, particularly those born before 28 weeks, which can cause hydrocephalus and parenchymal injury.
• Congenital brain infections: cytomegalovirus (CMV), toxoplasmosis, rubella, and Zika virus can cause brain malformations and injury in utero.

Perinatal causes (during labor and delivery) include hypoxic-ischemic encephalopathy (HIE) — oxygen deprivation during delivery, often associated with placental abruption, umbilical cord prolapse, or prolonged labor. HIE is the most recognized cause of CP but accounts for only approximately 10–15% of cases overall. Postnatal CP (after birth to age 3) may result from meningitis, encephalitis, non-accidental head trauma, or stroke.

Types of Cerebral Palsy

GMFCS: Functional Classification

The Gross Motor Function Classification System (GMFCS) is the standard five-level system for describing functional mobility in children with CP, based on self-initiated movement with emphasis on sitting, standing, and walking.

• Level I: Walks without limitations; may have difficulties with higher-level motor skills (running, jumping)
• Level II: Walks with limitations; difficulties with uneven terrain, stairs, and community environments; may use mobility device in some settings
• Level III: Walks using handheld mobility device; uses wheelchair for longer distances
• Level IV: Self-mobility with limitations; may use powered mobility outdoors; transported or uses power wheelchair in most settings
• Level V: Transported in all settings; limited voluntary movement; cannot maintain head and trunk position against gravity

GMFCS level is highly stable over time and strongly predicts functional outcomes, communication needs, educational support requirements, and lifetime care costs. The average cost of lifetime care for a person with CP is estimated at $921,000 (2023 dollars), with higher costs for individuals at GMFCS Levels IV and V.

Periventricular Leukomalacia on MRI

PVL appears on MRI as bilateral, symmetric signal abnormalities in the periventricular white matter — areas of T2/FLAIR hyperintensity or cystic change reflecting ischemic injury to the developing white matter. In premature infants, cranial ultrasound is the first-line imaging tool, detecting the cystic forms of PVL (cystic PVL) that carry the highest CP risk. Later MRI, typically performed at term-equivalent age or after, provides more detailed characterization of injury extent, myelination delays, and associated grey matter injury. MRI at term-equivalent age in premature infants can predict neurodevelopmental outcomes with reasonable accuracy — severe white matter injury predicts significant motor impairment, while mild injuries carry more variable prognosis.

Management: Spasticity Treatments

Spasticity management is central to CP care, aimed at reducing pain, preventing contractures and hip dislocation, improving function, and facilitating therapy participation.

• Botulinum toxin A injections: Administered into spastic muscles (typically gastrocnemius/soleus for equinus foot, hip adductors for scissor gait) under ultrasound guidance. Effects last 3–6 months; repeated injections are standard practice. Most effective for focal spasticity in GMFCS Levels I–III who are actively walking.
• Oral medications: Baclofen and diazepam reduce generalized spasticity but have significant sedation and cognitive side effects, limiting their utility in children.
• Intrathecal baclofen (ITB): A surgically implanted pump delivers baclofen directly into the intrathecal space, achieving significant spasticity reduction at 1/100th the oral dose, minimizing systemic side effects. Particularly effective for severe whole-body spasticity in GMFCS Levels IV–V.
• Selective Dorsal Rhizotomy (SDR): A surgical procedure that divides selected sensory nerve rootlets from the lumbar spinal cord, permanently reducing spasticity in the lower extremities. Best results are achieved in carefully selected children aged 3–8 with spastic diplegia, adequate muscle strength, and GMFCS Level II–III. Significant, durable improvement in gait has been demonstrated in long-term follow-up studies.

AAC Devices for Non-Speaking CP

Approximately 25–40% of people with CP have significant communication impairment — anarthria or dysarthria severe enough to limit functional speech. Augmentative and alternative communication (AAC) devices range from simple low-tech picture boards to sophisticated high-tech speech-generating devices (SGDs) with eye-gaze access for individuals with severe motor impairment. Modern AAC technology has transformed communication possibilities for non-speaking individuals with CP: children who cannot raise their arms can communicate complex thoughts, answer academic questions, and participate in social interactions through eye-gaze systems that track corneal reflection to select vocabulary.

Access to appropriate AAC is often delayed by assessment backlogs, funding barriers, and underestimation of cognitive potential in children with severe motor involvement. Research consistently shows that AAC does not hinder speech development — it supports it. Early provision of robust AAC, matched to the individual's cognitive and motor profile, is a standard recommendation of speech-language pathologists specializing in CP. Communication is not optional in a full life.

Lifespan and Aging with CP

The lifespan of people with CP at GMFCS Levels I–III approaches that of the general population with adequate medical support. People at Levels IV and V have reduced life expectancy, primarily from respiratory complications, aspiration pneumonia, and swallowing difficulties. The growing population of adults aging with CP presents new challenges: pain — particularly musculoskeletal pain from decades of abnormal movement patterns — becomes a major issue in mid-adulthood and beyond. Fatigue, joint deterioration, and loss of ambulatory function previously managed in childhood may reemerge as new management challenges in adults in their 40s and 50s. The Gross Motor Function Measure (GMFM) provides standardized outcome measurement across studies and clinical settings, tracking functional gains from therapy and surgery over time.